( ho do not meet the DSM-IV criteria and...)Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia,Health

ho do not meet the DSM-IV criteria, and experience considerable daytime impairment and symptom frequency. Study Estimates Insomnia Costs at $13.5 Billion Annually in the U.S. Labor Force -- The objective of this study was to estimate the annual indirect costs in the U.S. Labor Force of DSM-IV diagnosed chronic primary insomnia. -- Results showed that the annual indirect cost of chronic primary insomnia in the U.S. labor force, as diagnosed by the DSM-IV, is estimated to be $13.5 billion which reflects absenteeism from work directly attributable to an insomnia diagnosis, and productivity losses attributable to the insomnia-related incidence of accidents and chronic illnesses (depression, alcohol and/or substance abuse/dependence) -- The authors concluded that a DSM-IV diagnosis of insomnia leads to considerable productivity losses in the U.S. labor force. Interventions to reduce the severity of chronic primary insomnia among U.S. workers could substantially reduce its indirect cost burden.

Pharmaceutical Treatment of Insomnia Reduces Overall Economic Costs of Insomnia

    --  The objective of this study was to estimate the direct and indirect

        costs of treated and untreated insomnia in an employed population.

    --  Results showed that insomnia patients who were initially treated with

        a non-benzodiazepine hypnotic within two weeks of diagnosis had a much

        lower cost burden that those who were not treated for their insomnia.

        Demonstrating that treating insomnia was cost-effective relative to

        non-treatment, or delayed treatment.

Study Shows that Existing Next Day Impairment Measures May Not Capture True Impact of Insomnia

    --  The goal of this study was to evaluate the commonly used tests of

        "n
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Hana Biosciences Presents Data On Two Programs At the American
Society of Clinical Oncology Annual Meeting
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is
Subject of Two Presentations at Key Ophthalmology Meeting, ARVO
2007
3. Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for
Travellers Diarrhoea Caused by Campylobacter Successfully
Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone